Peter Dannenbaum | Vice President-Investor Relations |
Kenneth Frazier | Chairman and Chief Executive Officer |
Robert Davis | Chief Financial Officer |
Roger Perlmutter | Executive Vice President and President, Merck Research Laboratories |
Frank Clyburn | Executive Vice President and Chief Commercial Officer |
Michael Nally | Executive Vice President and Chief Marketing Officer |
Dean Li | Head of Discovery Research |
Steve Scala | Cowen and Company |
David Risinger | Morgan Stanley |
Tim Anderson | Wolfe Research |
Chris Schott | JP Morgan |
Mara Goldstein | Mizuho Securities |
Umer Raffat | Evercore |
Gregg Gilbert | Truist |
Navin Jacob | UBS |
Geoff Meacham | Bank of America Merrill Lynch |
Terence Flynn | Goldman Sachs |
Seamus Fernandez | Guggenheim Securities |
My name is Laura, and I will be your conference operator today. At this time, I would like to welcome everyone to the Merck & Co. Q3 Sales and Earnings Conference Call. All lines have been placed in mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session.